WO2018114728A1 - Polythérapie par anticorps bispécifique anti-ang2/vegf et anticorps bispécifique anti-her2 - Google Patents

Polythérapie par anticorps bispécifique anti-ang2/vegf et anticorps bispécifique anti-her2 Download PDF

Info

Publication number
WO2018114728A1
WO2018114728A1 PCT/EP2017/083187 EP2017083187W WO2018114728A1 WO 2018114728 A1 WO2018114728 A1 WO 2018114728A1 EP 2017083187 W EP2017083187 W EP 2017083187W WO 2018114728 A1 WO2018114728 A1 WO 2018114728A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
antibody
amino acid
bispecific anti
acid sequence
Prior art date
Application number
PCT/EP2017/083187
Other languages
English (en)
Inventor
Christian Klein
Werner Scheuer
Original Assignee
F. Hoffmann-La Roche Ag
Hoffmann-La Roche Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag, Hoffmann-La Roche Inc. filed Critical F. Hoffmann-La Roche Ag
Publication of WO2018114728A1 publication Critical patent/WO2018114728A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Definitions

  • the present invention relates to the combination therapy of an antibody a bispecific anti-ANG2/VEGF antibody and a bispecific anti-HER2 antibody that bind to domain II and domain IV of HER2.
  • Angiopoietins which play a key role in angiogenesis and blood vessel remodeling, are part of the pro-angiogenic armamentarium of growing tumors. Importantly they are one of the major factors leading to secondary resistance during anti-VEGF therapy (Saharinen, P., et al, Trends Mol Med 17 (2011) 347-362). Both angiopoietin-1 (Angl) and angiopoietin-2 (Ang2) are Tie2 -receptor ligands. While Angl tends to stabilize and matures blood vessel (Yancopoulos, G. D., et al, Nature 407 (2000) 242-248) Ang2 promotes tumor angiogenesis and growth by destabilizing blood vessels.
  • Ang2 thereby opposes Angl in its function (Cascone, T. et al, J Clin Oncol 30 (2012) 441-444).
  • blocking Ang2 but not Angl normalizes tumor blood vessels (Falcon, B. L., H. Hashizume, et al., Am J Pathol 175 (2009) 2159-2170) and helps to overcome acquired resistance towards anti-VEGF therapy (Chae, S. S., W. S. Kamoun, et al, Clin Cancer Res 16 (2010) 3618-3627; Thomas, M., et al. PLoS One 8 (2013) e54923).
  • the receptor family includes four distinct members, including epidermal growth factor receptor (EGFR or ErbBl), HER2 (ErbB2 or pl85"e"), HER3 (ErbB3) and HER4 (ErbB4 or tyro2).
  • EGFR epidermal growth factor receptor
  • HER2 ErbB2 or pl85"e
  • HER3 ErbB3
  • HER4 ErbB4 or tyro2
  • HER2 is a transmembrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation.
  • HER2 is a promising target for treatment of breast cancer as it was found to be overexpressed in about one-quarter of breast cancer patients (Bange et al, 2001, Nature Medicine 7:548).
  • the murine monoclonal antibody 4D5 is targeting HER2 specifically in HER2 overexpressing cancer cells, while having no effect on cells expressing physiological levels of HER2.
  • the humanized (4D5) monoclonal antibody (hu4D5) is commercially known as the drug Herceptin® (trastuzumab, rhuMAb HER2, US Patent No 5,821,337), which gained FDA marketing approval in late 1998.
  • Herceptin was the first monoclonal antibody developed for the treatment of HER2- positive breast cancer and has increased survival times for patients so that they are now the same as for patients with HER2 -negative breast cancer. Before Herceptin treatment, shorter survival outcomes were expected for patients diagnosed with HER2 -positive breast cancer, compared to patients with HER2 -negative disease. In the CLEOPATRA study, PERJETA in combination with Herceptin and chemotherapy has shown the extension of survival times for patients with this aggressive disease even further than Herceptin.
  • Pertuzumab (PERJETATM, rhuMab 2C4, US Patent No. 7,862,817) is a humanized monoclonal antibody, which is designed specifically to prevent the HER2 receptor from pairing (dimerising) with other HER receptors (EGFR/HERl, HER3 and HER4) on the surface of cells, a process that is believed to play a role in tumor growth and survival.
  • PERJETATM rhuMab 2C4, US Patent No. 7,862,8157
  • HER2 receptor EGFR/HERl, HER3 and HER4
  • the combination of PERJETA, Herceptin and chemotherapy is thought to provide a more comprehensive blockade of HER signaling pathways.
  • PERJETA is approved in combination with Herceptin (trastuzumab) and docetaxel in adult patients with HER2 -positive metastatic or locally recurrent unresectable breast cancer and gained FDA approval for neoadjuvant breast cancer treatment in September 2013.
  • Pertuzumab binds to domain II of HER2, essential for dimerization, while trastuzumab binds to domain IV of HER2.
  • bispecific, bivalent antibodies to HER2 that overcome trastuzumab resistance.
  • the bispecific, bivalent antibodies described therein are based on the native Trastuzumab and Pertuzumab sequences.
  • WO2010040508, WO2011117329, WO2012131078 relate to bispecific
  • WO2015/091738 relate to improved bispecific antibodies to HER2 that bind to that bind to domain II and domain IV of HER2.
  • The relate to optimizing the native Trastuzumab and Pertuzumab sequences and combining these optimized variants in two different improved bispecific, monovalent antibody formats leading to improved properties as compared to the combination of the monospecific antibodies rhuMab 2C4 and hu 4D5. Further the antibodies are superior to the bivalent antibody formats disclosed in Li et al, as they are monovalent and have the same molecular weight as the two monospecific antibodies Pertuzumab and Trastuzumab.
  • bispecific anti-ANG2/VEGF antibodies enhance the efficacy of bispecific anti-HER2 antibodies to treat cancers or delay progression of a tumor or the survival of a patient afflicted with cancer e.g. with a solid tumor.
  • the delay of progression, the longer survival as well as the potential of reduced doses with lower risk of side effects represent a major benefit for patients.
  • the bispecific anti-HER2 antibodies specifically bind to HER2 comprising a first antigen binding site specific for the domain II of HER2 and a second antigen binding site specific for the domain IV of HER2.
  • One aspect of the present invention is a bispecific anti-ANG2/VEGF antibody comprising a first antigen binding site specific for ANG2 and a second antigen binding site specific for VEGF; wherein the antibody is administered in combination with a bispecific anti-HER2 antibody comprising a first antigen binding site specific for the domain II of HER2 and a second antigen binding site specific for the domain IV of HER2 a) for use in treating cancer or, b) for use in delaying progression of cancer, or c) for use in prolonging the survival of a patient suffering from cancer.
  • Another aspect of the invention is pharmaceutical kit comprising: a bispecific anti-ANG2/VEGF antibody comprising a first antigen binding site specific for ANG2 and a second antigen binding site specific for the VEGF;
  • bispecific anti-HER2 antibody comprising a first antigen binding site specific for the domain II of HER2 and a second antigen binding site specific for the domain IV of HER2
  • the antibodies are to be administered in combination a) for use in treating cancer, or b) for use in delaying progression of cancer, or c) for use in prolonging the survival of a patient suffering from cancer.
  • the bispecific anti-ANG2/VEGF antibody is monovalent for both ANG2 and VEGF and the bispecific anti-HER2 antibody is monovalent for both the domain II and IV of HER2.
  • the bispecific anti-ANG2/VEGF antibody and the bispecific anti-HER2 antibody are both IgG antibodies.
  • the bispecific anti-ANG2/VEGF antibody comprises
  • the bispecific anti-HER2 antibody comprises
  • a heavy chain variable domain comprising amino acid sequence of SEQ ID NO: 11;
  • two light chain variable domains comprising amino acid sequence of SEQ ID NO: 13.
  • the bispecific anti-ANG2/VEGF antibody comprises
  • the bispecific anti-HER2 antibody comprises
  • the cancer is a solid tumor. In one embodiment of the invention the cancer is further characterized by HER2 expression. In one embodiment of the invention the cancer is further characterized by HER2 overexpression.
  • ANG-2 Human angiopoietin-2 (ANG-2) (alternatively abbreviated with ANGPT2 or ANG2) (SEQ ID No: 15) is described in Maisonpierre, P.C., et al, Science 277 (1997) 55-60 and Cheung, A.H., et al, Genomics 48 (1998) 389-91.
  • the angiopoietins-1 and -2 (ANG-1(SEQ ID No: 108) and ANG-2 (SEQ ID No: 107) were discovered as ligands for the Ties, a family of tyrosine kinases that is selectively expressed within the vascular endothelium. Yancopoulos, G.D., et al, Nature 407 (2000) 242-48.
  • Angiopoietin-3 and -4 may represent widely diverged counterparts of the same gene locus in mouse and man.
  • ANG-1 and ANG-2 were originally identified in tissue culture experiments as agonist and antagonist, respectively (see for ANG-1 : Davies, S., et al, Cell, 87 (1996) 1161-1169; and for ANG-2: Maisonpierre, P.C., et al, Science 277 (1997) 55-60). All of the known angiopoietins bind primarily to Tie2, and both Ang-1 and
  • ANG-2 had the opposite effect and promoted blood vessel destabilization and regression in the absence of the survival factors VEGF or basic fibroblast growth factor.
  • ANG-2 might be a complex regulator of vascular remodeling that plays a role in both vessel sprouting and vessel regression. Supporting such roles for ANG-2, expression analyses reveal that ANG-2 is rapidly induced, together with VEGF, in adult settings of angiogenic sprouting, whereas ANG-2 is induced in the absence of VEGF in settings of vascular regression.
  • ANG-2 specifically binds to the same endothelial-specific receptor, Tie-2, which is activated by Ang-1, but has context-dependent effects on its activation. Maisonpierre, P.C., et al., Science 277 (1997) 55-60.
  • human ANG2 refers to the human protein angiopoietin 2 (SEQ ID NO: 15).
  • binding to human ANG2 or “specifically binding to human ANG2” or “which binds to human ANG2” or “anti- ANG2 antibody” refers to an antibody specifically binding to the human ANG2 antigen with a binding affinity of KD-value of 1.0 x 10 "8 mo 1/1 or lower, in one embodiment of a KD-value of 1.0 xlO 9 mo 1/1 or lower.
  • the binding affinity is determined with a standard binding assay, such as surface plasmon resonance technique (BIAcore®, GE- Healthcare Uppsala, Sweden).
  • an "antibody binding to human ANG2" as used herein refers to an antibody specifically binding to the human ANG2 antigen with a binding affinity of KD 1.0 x 10 "8 mo 1/1 or lower (in one embodiment 1.0 x 10 ⁇ 8 mol/1 - 1.0 x 10 ⁇ 13 mol/1), in one embodiment of a KD 1.0 xlO 9 mo 1/1 or lower (in one embodiment 1.0 x 10 ⁇ 9 mol/1 - 1.0 x 10 "13 mol/1).
  • antibodies bispecific anti-ANG2/VEGF antibody that binds to human ANG-2 and that binds to human VEGF which are useful for the treatment described herein are e.g. disclosed and described in detail in
  • WO2010/040508, WO 2011/117329 or WO2012/131078 can be used within the bispecific antibody using the anti-VEGF binding arms and structures described in
  • the bispecific antibody that binds to human ANG-2 and that binds to human VEGF comprises
  • the bispecific antibody that binds to human ANG-2 and that binds to human VEGF comprises the amino acid sequences of SEQ ID NO: 7, of SEQ ID NO: 8, of SEQ ID NO: 9, and of SEQ ID NO: 10.
  • the receptor family includes four distinct members, including epidermal growth factor receptor (EGFR or ErbBl), HER2 (ErbB2 or pl85"e"), HER3 (ErbB3) and HER4 (ErbB4 or tyro2).
  • EGFR epidermal growth factor receptor
  • HER2 ErbB2 or pl85"e
  • HER3 ErbB3
  • HER4 ErbB4 or tyro2
  • HER2 is a transmembrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation.
  • HER2 is a promising target for treatment of breast cancer as it was found to be overexpressed in about one-quarter of breast cancer patients (Bange et al, 2001, Nature Medicine 7:548).
  • ErbB2 ErbB2 receptor
  • c-Erb-B2 HER2
  • HER2 HER2
  • a bispecific anti-HER2 antibody and “a bispecific antibody that specifically binds to HER2” are used interchangeably and refer to a bispecific antibody that is capable of binding HER2 on both domains II and IV, respectively, with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting cells expressing HER2.
  • the extent of binding of a bispecific antibody that specifically binds to HER2 on both domains II and IV to an unrelated, non-HER2 protein is less than about 10% of the binding of the antibody to HER2 as measured, e.g., by an Enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR) based assays (e.g. Biacore) or flow cytometry (FACS).
  • ELISA Enzyme-linked immunosorbent assay
  • SPR surface plasmon resonance
  • Biacore Biacore
  • FACS flow cytometry
  • a bispecific antibody that specifically binds to HER2 has a dissociation constant (Kd) of
  • Typical bispecific anti-HER2 antibody that binds to the domain II of human HER2 and that binds to the domain IV of human HER2 which are useful for the treatment described herein are e.g. disclosed and described in detail in WO2015/091738.
  • the bispecific anti-HER2 antibody that binds to the domain II of human HER2 and that binds to the domain IV of human HER2 comprises
  • a heavy chain variable domain comprising amino acid sequence of SEQ ID NO: 11;
  • the bispecific anti-HER2 antibody that binds to the domain II of human HER2 and that binds to the domain IV of human HER2 comprises
  • the bispecific anti-ANG2/VEGF antibody is monovalent for both ANG2 and VEGF refers to a bispecific antibody with only one antigen binding site for ANG2 and only one antigen binding site for VEGF.
  • the bispecific anti-HER2 antibody is monovalent for both the domain II and IV of HER2
  • epitope denotes a protein determinant of the antigen capable of specifically binding to an antibody. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually epitopes have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.
  • variable domain denotes each of the pair of light and heavy chain domains which are involved directly in binding the antibody to the antigen.
  • the variable light and heavy chain domains have the same general structure and each domain comprises four framework (FR) regions whose sequences are widely conserved, connected by three "hypervariable regions” (or complementary determining regions, CDRs).
  • the framework regions adopt a beta-sheet conformation and the CDRs may form loops connecting the beta- sheet structure.
  • the CDRs in each chain are held in their three-dimensional structure by the framework regions and form together with the CDRs from the other chain the antigen binding site.
  • the antibody's heavy and light chain CDR3 regions play a particularly important role in the binding specificity/affinity of the antibodies according to the invention and therefore provide a further object of the invention.
  • antigen-binding site of an antibody when used herein refer to the amino acid residues of an antibody which are responsible for antigen-binding.
  • the antigen-binding site of an antibody comprises amino acid residues from the "complementary determining regions" or "CDRs".
  • the antigen binding site comprises a heavy chain variable domain
  • the antigen binding site comprise a heavy chain variable domain and a light chain variable domain (both forming together the antigen binding site).
  • "Framework" or "FR” regions are those variable domain regions other than the hypervariable region residues as herein defined.
  • the light and heavy chain variable domains of an antibody comprise from N- to C-terminus the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
  • CDR3 of the heavy chain is the region which contributes most to antigen binding and defines the antibody's properties.
  • CDR and FR regions are determined according to the standard definition of Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) and/or those residues from a "hypervariable loop".
  • nucleic acid or “nucleic acid molecule”, as used herein, are intended to include DNA molecules and RNA molecules.
  • a nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded DNA.
  • amino acid denotes the group of naturally occurring carboxy alpha-amino acids comprising alanine (three letter code: ala, one letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine (cys, C), glutamine (gin, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y), and valine (val, V).
  • alanine three letter code: ala, one letter code: A
  • arginine arg, R
  • Fc part of an antibody is not involved directly in binding of an antibody to an antigen, but exhibit various effector functions.
  • a "Fc part of an antibody” is a term well known to the skilled artisan and defined on the basis of papain cleavage of antibodies.
  • antibodies or immunoglobulins are divided in the classes: IgA, IgD, IgE, IgG and IgM, and several of these may be further divided into subclasses
  • immunoglobulins are called a, ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
  • the Fc part of an antibody is directly involved in ADCC (antibody-dependent cell-mediated cytotoxicity) and CDC (complement- dependent cytotoxicity) based on complement activation, Clq binding and Fc receptor binding.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • CDC complement- dependent cytotoxicity
  • Complement activation is initiated by binding of complement factor Clq to the Fc part of most IgG antibody subclasses. While the influence of an antibody on the complement system is dependent on certain conditions, binding to Clq is caused by defined binding sites in the Fc part.
  • binding sites are known in the state of the art and described e.g. by Boackle, R.J., et al, Nature 282 (1979) 742-743; Lukas, T.J., et al, J. Immunol. 127 (1981) 2555- 2560; Brunhouse, R., and Cebra, J. J., Mol. Immunol. 16 (1979) 907-917; Burton, D.R., et al, Nature 288 (1980) 338-344; TNeillsen, J.E., et al, Mol. Immunol. 37 (2000) 995-1004; Idusogie, E.E., et al, J. Immunol.164 (2000) 4178-4184; Hezareh, M., et al, J. Virology 75 (2001) 12161-12168; Morgan, A., et al,
  • binding sites are e.g. L234, L235, D270, N297, E318, K320, K322, P331 and P329 (numbering according to EU index of Kabat, E.A., see below).
  • Antibodies of subclass IgGl, IgG2 and IgG3 usually show complement activation and Clq and C3 binding, whereas IgG4 do not activate the complement system and do not bind Clq and C3.
  • the antibodies described herein are of human IgG class (i.e. of IgGl, IgG2, IgG3 or IgG4 subclass).
  • the antibodies described herein are of human IgGl subclass or of human IgG4 subclass. In one embodiment the described herein are of human IgGl subclass. In one embodiment the antibodies described herein are of human IgG4 subclass.
  • the antibody according to the invention comprises an Fc part derived from human origin and preferably all other parts of the human constant regions.
  • Fc part derived from human origin denotes a Fc part which is either a Fc part of a human antibody of the subclass IgGl, IgG2, IgG3 or IgG4, preferably a Fc part from human IgGl subclass, a mutated Fc part from human IgGl subclass (in one embodiment with a mutation on L234A + L235A), a Fc part from human IgG4 subclass or a mutated Fc part from human IgG4 subclass (in one embodiment with a mutation on S228P).
  • the antibody described herein is characterized in that the constant chains are of human origin. Such constant chains are well known in the state of the art and e.g. described by Kabat, E.A., (see e.g. Johnson, G. and Wu, T.T., Nucleic Acids Res. 28 (2000) 214-218).
  • the invention comprises a method for the treatment of a patient in need of therapy, characterized by administering to the patient a therapeutically effective amount of the bispecific anti-ANG2/VEGF antibody described herein in combination with administering a therapeutically effective amount of a bispecific anti-HER2 antibody described herein.
  • the invention comprises the use of the bispecific anti-ANG2/VEGF antibody described herein in combination with a bispecific anti-HER2 antibody as described herein for the described therapy.
  • the antibodies described herein are preferably produced by recombinant means.
  • Such methods are widely known in the state of the art and comprise protein expression in prokaryotic and eukaryotic cells with subsequent isolation of the antibody polypeptide and usually purification to a pharmaceutically acceptable purity.
  • protein expression nucleic acids encoding light and heavy chains or fragments thereof are inserted into expression vectors by standard methods.
  • prokaryotic or eukaryotic host cells such as CHO cells, NS0 cells, SP2/0 cells, HEK293 cells, COS cells, yeast, or E. coli cells
  • the antibody is recovered from the cells (from the supernatant or after cells lysis).
  • Recombinant production of antibodies is well-known in the state of the art and described, for example, in the review articles of Makrides, S.C., Protein Expr. Purif. 17 (1999) 183-202; Geisse, S., et al, Protein Expr. Purif. 8 (1996) 271-282; Kaufman, R.J., Mol. Biotechnol. 16 (2000) 151-161; Werner, R.G., Drug Res. 48 (1998) 870-880.
  • the antibodies may be present in whole cells, in a cell lysate, or in a partially purified, or substantially pure form. Purification is performed in order to eliminate other cellular components or other contaminants, e.g. other cellular nucleic acids or proteins, by standard techniques, including alkaline/SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis, and others well known in the art. See Ausubel, F., et al, ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987).
  • variable domains Cloning of variable domains is described by Orlandi, R., et al, Proc.
  • HEK 293 A preferred transient expression system (HEK 293) is described by Schlaeger, E.-J. and Christensen, K., in Cytotechnology 30 (1999) 71-83, and by
  • the heavy and light chain variable domains according to the invention are combined with sequences of promoter, translation initiation, constant region, 3' untranslated region, polyadenylation, and transcription termination to form expression vector constructs.
  • the heavy and light chain expression constructs can be combined into a single vector, co-transfected, serially transfected, or separately transfected into host cells which are then fused to form a single host cell expressing both chains.
  • control sequences that are suitable for prokaryotes include a promoter, optionally an operator sequence, and a ribosome binding site.
  • Eukaryotic cells are known to utilize promoters, enhancers and polyadenylation signals.
  • Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence.
  • DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide;
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or
  • a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
  • "operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading frame.
  • enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
  • the monoclonal antibodies are suitably separated from the culture medium by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. DNA and RNA encoding the monoclonal antibodies are readily isolated and sequenced using conventional procedures. The hybridoma cells can serve as a source of such DNA and RNA.
  • the DNA may be inserted into expression vectors, which are then transfected into host cells such as HEK 293 cells, CHO cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of recombinant monoclonal antibodies in the host cells.
  • host cells such as HEK 293 cells, CHO cells, or myeloma cells that do not otherwise produce immunoglobulin protein
  • the expressions "cell”, “cell line”, and “cell culture” are used interchangeably and all such designations include progeny.
  • the words “transformants” and “transformed cells” include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Variant progeny that have the same function or biological activity as screened for in the originally transformed cell are included.
  • the present invention provides a composition, e.g. a pharmaceutical composition, containing one or a combination of monoclonal antibodies, or the antigen-binding portion thereof, of the present invention, formulated together with a pharmaceutically acceptable carrier.
  • a composition e.g. a pharmaceutical composition, containing one or a combination of monoclonal antibodies, or the antigen-binding portion thereof, of the present invention, formulated together with a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption/resorption delaying agents, and the like that are physiologically compatible.
  • the carrier is suitable for injection or infusion.
  • a composition of the present invention can be administered by a variety of methods known in the art. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results.
  • Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the preparation of sterile injectable solutions or dispersion.
  • the use of such media and agents for pharmaceutically active substances is known in the art.
  • the carrier can be, for example, an isotonic buffered saline solution.
  • the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient (effective amount).
  • the selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a method of treating when applied to, for example, cancer refers to a procedure or course of action that is designed to reduce or eliminate the number of cancer cells in a patient, or to alleviate the symptoms of a cancer.
  • a method of treating does not necessarily mean that the cancer cells or other disorder will, in fact, be eliminated, that the number of cells or disorder will, in fact, be reduced, or that the symptoms of a cancer or other disorder will, in fact, be alleviated.
  • a method of treating cancer will be performed even with a low likelihood of success, but which, given the medical history and estimated survival expectancy of a patient, is nevertheless deemed to induce an overall beneficial course of action.
  • administered in combination with or “co-administration”, “coadministering”, “combination therapy” or “combination treatment” refer to the administration of the bispecific anti-ANG2/VEGF antibody as described herein, and the bispecific anti-HER2 antibody as described herein e.g. as separate formulations/applications (or as one single formulation/application).
  • the co-administration can be simultaneous or sequential in either order, wherein preferably there is a time period while both (or all) active agents simultaneously exert their biological activities.
  • Said antibody and said further agent are coadministered either simultaneously or sequentially (e.g. intravenous (i.v.) through a continuous infusion.
  • both therapeutic agents are co-administered sequentially the dose is administered either on the same day in two separate administrations, or one of the agents is administered on day 1 and the second is co- administered on day 2 to day 7, preferably on day 2 to 4.
  • the term “sequentially” means within 7 days after the dose of the first component, preferably within 4 days after the dose of the first component; and the term “simultaneously” means at the same time.
  • co-administration with respect to the maintenance doses of bispecific anti-ANG2/VEGF antibody and/or bispecific anti-HER2 antibody mean that the maintenance doses can be either coadministered simultaneously, if the treatment cycle is appropriate for both drugs, e.g. every week.
  • the further agent is e.g. administered e.g. every first to third day and said antibody is administered every week.
  • the maintenance doses are co-administered sequentially, either within one or within several days. It is self-evident that the antibodies are administered to the patient in a
  • terapéuticaally effective amount (or simply “effective amount") which is the amount of the respective compound or combination that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • patient or “subject” preferably refers to a human in need of treatment of cancer, or a precancerous condition or lesion.
  • patient can also refer to non-human animals, e.g. mammals such as mice, dogs, cats, horses, cows, pigs, sheep and non-human primates, among others, that are in need of treatment.
  • the amount of co-administration and the timing of co-administration will depend on the type (species, gender, age, weight, etc.) and condition of the patient being treated and the severity of the disease or condition being treated.
  • Said bispecific anti-ANG2/VEGF antibody and further agent are suitably co-administered to the patient at one time or over a series of treatments e.g. on the same day or on the day after.
  • 0.1 mg /kg to 50 mg/kg (e.g. 0.1-20 mg/kg) of said bispecific anti-ANG2/VEGF antibody and/or bispecific anti-HER2 antibody; is an initial candidate dosage for co-administration of both drugs to the patient
  • the invention comprises the use of the antibodies according to the invention for the treatment of a patient suffering from cancer, especially from colon cancer, ovarian cancer, glioblastoma, gastric cancer, pancreatic cancer, breast cancer, lung cancer, hepatocellular cancer.
  • a chemotherapeutic agent in addition to the bispecific anti-ANG2/VEGF antibody in combination with the bispecific anti-HER2 antibody also a chemotherapeutic agent can be administered.
  • additional chemotherapeutic agents which may be administered with bispecific anti-ANG2/VEGF antibody as described herein and the bispecific anti-HER2 antibody as described herein , include, but are not limited to, anti-neoplastic agents including alkylating agents including: nitrogen mustards, such as mechlorethamine, cyclophosphamide, ifosfamide, melphalan and chlorambucil; nitrosoureas, such as carmustine (BCNU), lomustine (CCNU), and semustine (methyl-CCNU); Temodal(TM) (temozolamide), ethylenimines/methylmelamine such as thriethylenemelamine (TEM), triethylene, thiophosphoramide (thiotepa), hexamethylmelamine (HMM, altretamine); alkyl sulfonates such as busulfan; triazines such as dacarbazine (DTIC); antimetabolites including folic acid analogs such as methotre
  • therapies targeting epigenetic mechanism including, but not limited to, histone deacetylase inhibitors, demethylating agents (e.g., Vidaza) and release of transcriptional repression (ATRA) therapies can also be combined with the antigen binding proteins.
  • the chemotherapeutic agent is selected from the group consisting of taxanes (like e.g.
  • paclitaxel Taxol
  • docetaxel Taxotere
  • modified paclitaxel e.g., Abraxane and Opaxio
  • doxorubicin sunitinib (Sutent)
  • sorafenib Nexavar
  • doxorubicin doxorubicin
  • sunitinib Sunitinib
  • sorafenib Nexavar
  • other multikinase inhibitors oxaliplatin
  • cisplatin and carboplatin etoposide
  • gemcitabine etoposide
  • vinblastine e.g. the chemotherapeutic agent is selected from the group consisting of taxanes (like e.g. taxol (paclitaxel), docetaxel (Taxotere), modified paclitaxel (e.g. Abraxane and
  • the additional chemotherapeutic agent is selected from 5-fluorouracil (5-FU), leucovorin, irinotecan, or oxaliplatin.
  • the chemotherapeutic agent is 5-fluorouracil, leucovorin and irinotecan (FOLFIRI).
  • the chemotherapeutic agent is 5- fluorouracil, and oxaliplatin (FOLFOX).
  • combination therapies with additional chemotherapeutic agents include, for instance, therapies taxanes (e.g., docetaxel or paclitaxel) or a modified paclitaxel (e.g., Abraxane or Opaxio), doxorubicin), capecitabine and/or bevacizumab (Avastin) for the treatment of breast cancer; therapies with carboplatin, oxaliplatin, cisplatin, paclitaxel, doxorubicin (or modified doxorubicin
  • topotecan for ovarian cancer
  • therapies with taxol and/or carboplatin for the treatment of lung cancer are particularly useful.
  • the additional chemotherapeutic agent is selected from the group of taxanes (docetaxel or paclitaxel or a modified paclitaxel (Abraxane or Opaxio), doxorubicin, capecitabine and/or bevacizumab for the treatment of breast cancer.
  • bispecific anti-ANG2/VEGF antibody/ bispecific anti- HER2 antibody combination therapy no additional chemotherapeutic agents are administered.
  • the invention comprises also a method for the treatment of a patient suffering from such disease.
  • the invention further provides a method for the manufacture of a pharmaceutical composition
  • a pharmaceutical composition comprising an effective amount of an antibody according to the invention together with a pharmaceutically acceptable carrier and the use of the antibody according to the invention for such a method.
  • the invention further provides the use of an antibody according to the invention in an effective amount for the manufacture of a pharmaceutical agent, preferably together with a pharmaceutically acceptable carrier, for the treatment of a patient suffering from cancer.
  • the invention also provides the use of an antibody according to the invention in an effective amount for the manufacture of a pharmaceutical agent, preferably together with a pharmaceutically acceptable carrier, for the treatment of a patient suffering from cancer.
  • variable heavy chain domain VH of ⁇ ANG-2> Ang2i_LC06 SEQ ID NO: 4 variable light chain domain VL of ⁇ ANG-2> Ang2i_LC06
  • variable light chain domain VL of ⁇ VEGF> bevacizumab SEQ ID NO 7 bispecific anti-ANG2/VEGF antibody heavy chain 1
  • SEQ ID NO 10 bispecific anti-ANG2/VEGF antibody light chain 2
  • SEQ ID NO 14 bispecific anti-HER2 antibody heavy chain 1
  • SEQ ID NO 16 bispecific anti-HER2 antibody light chain
  • VEGF vascular endothelial growth factor
  • SEQ ID NO 20 exemplary human HER2 domain II
  • a bispecific anti-ANG2/VEGF antibody comprising a first antigen binding site specific for ANG2 and a second antigen binding site specific for the VEGF; wherein the antibody is administered in combination with a bispecific anti-HER2 antibody comprising a first antigen binding site specific for the domain II of HER2 and a second antigen binding site specific for the domain IV of HER2
  • bispecific anti- ANG2/VEGF antibody is monovalent for both ANG2 and VEGF
  • bispecific anti-HER2 antibody is monovalent for both the domain II and IV of HER2.
  • bispecific anti-ANG2/VEGF antibody and the bispecific anti- HER2 antibody are both IgG antibodies.
  • the bispecific anti-ANG2/VEGF antibody comprises
  • bispecific anti-HER2 antibody comprises
  • a heavy chain variable domain comprising amino acid sequence of SEQ ID NO: 11;
  • two light chain variable domains comprising amino acid sequence of SEQ ID NO: 13.
  • bispecific anti-ANG2/VEGF antibody comprises
  • bispecific anti-HER2 antibody comprises
  • the cancer is lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvi
  • the antibody for use according to any one of the preceding embodiments, wherein the bispecific anti-ANG2/VEGF and the bispecific anti-HER2 antibody are administered simultaneously.
  • the antibody for use according to any one of the preceding embodiments, wherein the bispecific anti-ANG2/VEGF and the bispecific anti-HER2 antibody are administered sequentially.
  • a pharmaceutical kit comprising: a bispecific anti-ANG2/VEGF antibody comprising a first antigen binding site specific for ANG2 and a second antigen binding site specific for the VEGF;
  • bispecific anti-HER2 antibody comprising a first antigen binding site specific for the domain II of HER2 and a second antigen binding site specific for the domain IV of HER2
  • antibodies are to be administered in combination a) for use in treating cancer, or b) for use in delaying progression of cancer, or c) for use in prolonging the survival of a patient suffering from cancer.
  • bispecific anti-HER2 antibody comprises
  • a heavy chain variable domain comprising amino acid sequence of SEQ ID NO: 11;
  • two light chain variable domains comprising amino acid sequence of SEQ ID NO: 13.
  • bispecific anti-HER2 antibody comprises
  • kits according to any one of the preceding embodiments, wherein the bispecific anti-ANG2/VEGF and the bispecific anti-HER2 antibody are to be administered simultaneously.
  • a bispecific anti-HER2 antibody comprising a first antigen binding site specific for the domain II of HER2 and a second antigen binding site specific for the domain IV of HER2; wherein the antibody is administered in combination with a bispecific anti-ANG2/VEGF comprising a first antigen binding site specific for ANG2 and a second antigen binding site specific for the VEGF
  • the bispecific anti-ANG2/VEGF antibody is monovalent for both ANG2 and VEGF, wherein the bispecific anti-HER2 antibody is monovalent for both the domain II and IV of HER2.
  • the antibody for use according to any one of the preceding embodiments, wherein the bispecific anti-ANG2/VEGF antibody and the bispecific anti- HER2 antibody are both IgG antibodies.
  • bispecific anti-HER2 antibody comprises
  • a heavy chain variable domain comprising amino acid sequence of SEQ ID NO: 11;
  • two light chain variable domains comprising amino acid sequence of SEQ ID NO: 13.
  • bispecific anti-ANG2/VEGF antibody comprises
  • bispecific anti-HER2 antibody comprises
  • the cancer is lung cancer, non small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis
  • the antibody for use according to any one of the preceding embodiments, wherein the bispecific anti-ANG2/VEGF and the bispecific anti-HER2 antibody are administered simultaneously.
  • the antibody for use according to any one of the preceding embodiments, wherein the bispecific anti-ANG2/VEGF and the bispecific anti-HER2 antibody are administered sequentially.
  • a bispecific anti-ANG2/VEGF antibody comprising a first antigen binding site specific for ANG2 and a second antigen binding site specific for the VEGF and a bispecific anti-HER2 antibody comprising a first antigen binding site specific for the domain II of HER2 and a second antigen binding site specific for the domain IV of HER2; wherein the antibodies are administered in combination
  • a) for use in treating cancer or b) for use in delaying progression of cancer, or c) for use in prolonging the survival of a patient suffering from cancer.
  • bispecific anti- ANG2/VEGF antibody is monovalent for both ANG2 and VEGF
  • bispecific anti-HER2 antibody is monovalent for both the domain II and IV of HER2.
  • bispecific anti-ANG2/VEGF antibody and the bispecific anti- HER2 antibody are both IgG antibodies.
  • bispecific anti-ANG2/VEGF antibody comprises
  • bispecific anti-HER2 antibody comprises
  • a heavy chain variable domain comprising amino acid sequence of SEQ ID NO: 11;
  • two light chain variable domains comprising amino acid sequence of SEQ ID NO: 13.
  • bispecific anti-ANG2/VEGF antibody comprises
  • bispecific anti-HER2 antibody comprises
  • the cancer is lung cancer, non small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of
  • the antibody for use according to any one of the preceding embodiments, wherein the bispecific anti-ANG2/VEGF and the bispecific anti-HER2 antibody are administered simultaneously.
  • the antibody for use according to any one of the preceding embodiments, wherein the bispecific anti-ANG2/VEGF and the bispecific anti-HER2 antibody are administered sequentially.
  • a bispecific anti-ANG2/VEGF antibody comprising a first antigen binding site specific for ANG2 and a second antigen binding site specific for the VEGF; for the manufacture of a medicament a) for use in treating cancer, or b) for use in delaying progression of cancer, or b) for use in prolonging the survival of a patient suffering from cancer;
  • the antibody is administered in combination with a bispecific anti- HER2 antibody comprising a first antigen binding site specific for the domain II of HER2 and a second antigen binding site specific for the domain IV of HER2.
  • a bispecific anti- HER2 antibody comprising a first antigen binding site specific for the domain II of HER2 and a second antigen binding site specific for the domain IV of HER2.
  • the bispecific anti- ANG2/VEGF antibody is monovalent for both ANG2 and VEGF
  • the bispecific anti-HER2 antibody is monovalent for both the domain II and IV of HER2.
  • the bispecific anti-ANG2/VEGF antibody and the bispecific anti-HER2 antibody are both IgG antibodies.
  • the bispecific anti-ANG2/VEGF antibody comprises
  • bispecific anti-HER2 antibody comprises
  • two light chain variable domains comprising amino acid sequence of SEQ ID NO: 13.
  • bispecific anti-ANG2/VEGF antibody comprises
  • bispecific anti-HER2 antibody comprises
  • the cancer is lung cancer, non small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, me
  • the bispecific anti-ANG2/VEGF and the bispecific anti-HER2 antibody are administered simultaneously.
  • the bispecific anti-ANG2/VEGF and the bispecific anti-HER2 antibody are administered sequentially.
  • a method of treatment wherein a bispecific anti-ANG2/VEGF antibody comprising a first antigen binding site specific for ANG2 and a second antigen binding site specific for the VEGF is administered in combination with a bispecific anti-HER2 antibody comprising a first antigen binding site specific for the domain II of HER2 and a second antigen binding site specific for the domain IV of HER2, wherein the treatment is a) for use in treating cancer , or b) for use in delaying progression of cancer, or b) for use in prolonging the survival of a patient suffering from cancer.
  • bispecific anti-ANG2/VEGF antibody comprises
  • bispecific anti-HER2 antibody comprises
  • a heavy chain variable domain comprising amino acid sequence of SEQ ID NO: 11;
  • two light chain variable domains comprising amino acid sequence of SEQ ID NO: 13.
  • bispecific anti-ANG2/VEGF antibody comprises
  • bispecific anti-HER2 antibody comprises
  • the cancer is lung cancer, non small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the pen
  • the method according to any one of the preceding embodiments, wherein the bispecific anti-ANG2/VEGF and the bispecific anti-HER2 antibody are administered simultaneously.
  • the method according to any one of the preceding embodiments, wherein the bispecific anti-ANG2/VEGF and the bispecific anti-HER2 antibody are administered sequentially.
  • the interaction ELISA was performed on 384 well microtiter plates (MicroCoat, DE, Cat.No. 464718) at RT. After each incubation step plates were washed 3 times with PBST. ELISA plates were coated with 5 ⁇ g/ml Tie-2 protein for 1 hour (h).
  • XMabl a bispecific antibody that binds to human ANG2 and to human VEGF (see WO2011/117329 and sequences SEQ ID NOs: l l- 14, showed an inhibition of ANG-2 binding to Tie-2 (ANG2/Tie2 receptor interaction inhibition) with an IC50 of 12 nM.
  • XMabl a bispecific antibody that binds to human ANG2 and to human VEGF (see WO2011/117329 and sequences SEQ ID NOs: l l- 14, showed an inhibition of ANG-2 binding to Tie-2 (ANG2/Tie2 receptor interaction inhibition) with an IC50 of 12 nM.
  • the bispecific HER2 antibody is a bispecific HER2 antibody with a common light chain including the two heavy chain variable domains of SEQ ID NOs: 11-12, and two common light chain variable domains of SEQ ID NO: 13.
  • the antibody was prepared as described in WO2015/091738 (comprising the two heavy chains of SEQ ID NOs: 14-15 and two identical common light chains of SEQ ID NO: 16.
  • Cell line KPL4
  • This human breast cancer cell line has been established from the malignant pleural effusion of a breast cancer patient with an inflammatory skin metastasis.
  • Cells have been provided by Professor J. Kurebayashi (Kawasaki Medical School, Kurashiki, Japan). Tumor cells are routinely cultured in DMEM medium (PAN Biotech,
  • mice Female SCID beige (C.B.-17) mice; age 10-12 weeks; body weight 18-20 g (Charles River Germany, Sulzfeld); body weight >20 g are maintained under specific-pathogen-free condition with daily cycles of 12 h light /12 h darkness according to international guidelines (GV-Solas; Felasa; TierschG). After arrival animals are housed in the quarantine part of the animal facility for one week to get accustomed to new environment and for observation. Continuous health monitoring is carried out on regular basis. Diet food (Alltromin) and water are provided ad libitum. The experimental study was reviewed and approved by local government.
  • Tumor cell injection At the day of injection tumor cells are harvested (trypsin-EDTA) from culture flasks (Greiner TriFlask) and transferred into 50 ml culture medium, washed once and resuspended in PBS. After an additional washing step with PBS and filtration (cell strainer; Falcon 0 ⁇ ) the final cell titer is adjusted to 1.5 x 10e8 / ml. Tumor cell suspension is carefully mixed with transfer pipette to avoid cell aggregation.
  • Anesthesia is performed using a Stephens inhalation unit for small animals with preincubation chamber (plexiglas), individual mouse nose-mask (silicon) and not flammable or explosive anesthesia compound Isoflurane (Pharmacia-Upjohn, Germany) in a closed circulation system.
  • a Stephens inhalation unit for small animals with preincubation chamber (plexiglas), individual mouse nose-mask (silicon) and not flammable or explosive anesthesia compound Isoflurane (Pharmacia-Upjohn, Germany) in a closed circulation system.
  • KPL-4 cells (3 x 10e6 cells) are injected orthotopically in a volume of 20 ⁇ (using a Hamilton microliter syringe and a 30Gxl/2" needle) into the right penultimate inguinal mammary fat pad of each anesthetized mouse.
  • the cell suspension is injected through the skin under the nipple using.
  • mice were randomized for tumor volume of 85mm 3 and subsequently treated once weekly for 4 weeks with a dosage of 3 mg/kg.
  • the bispecific anti-HER2 antibody was given first and the bispecific Ang2/VEGF antibody was given 24 hrs thereafter.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne la combinaison d'anticorps bispécifiques.
PCT/EP2017/083187 2016-12-20 2017-12-18 Polythérapie par anticorps bispécifique anti-ang2/vegf et anticorps bispécifique anti-her2 WO2018114728A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16205444.9 2016-12-20
EP16205444 2016-12-20

Publications (1)

Publication Number Publication Date
WO2018114728A1 true WO2018114728A1 (fr) 2018-06-28

Family

ID=57570843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/083187 WO2018114728A1 (fr) 2016-12-20 2017-12-18 Polythérapie par anticorps bispécifique anti-ang2/vegf et anticorps bispécifique anti-her2

Country Status (1)

Country Link
WO (1) WO2018114728A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
US11155610B2 (en) 2014-06-28 2021-10-26 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2022057888A1 (fr) * 2020-09-17 2022-03-24 江苏恒瑞医药股份有限公司 Molécule de liaison à l'antigène bispécifique se liant spécifiquement au vegf et à l'ang-2
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434A1 (fr) 1987-03-18 1989-03-22 Medical Res Council Anticorps alteres.
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
WO2003030833A2 (fr) 2001-10-11 2003-04-17 Amgen Inc. Agents de liaison spécifiques de l'angiopoïétine-2
WO2006068953A2 (fr) 2004-12-21 2006-06-29 Astrazeneca Ab Anticorps dirigés contre l'angiopoïétine 2 et leurs utilisations
WO2009097325A1 (fr) 2008-01-28 2009-08-06 Medimmune Limited Anticorps stabilisés contre l'angiopoïétine-2 et leurs utilisations
WO2009105269A1 (fr) 2008-02-20 2009-08-27 Amgen Inc. Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
WO2010040508A1 (fr) 2008-10-08 2010-04-15 F. Hoffmann-La Roche Ag Anticorps anti-vegf/anti-ang-2 bispécifiques
WO2010069532A1 (fr) 2008-12-16 2010-06-24 F. Hoffmann-La Roche Ag Anticorps dirigés contre l'angiopoïétine 2 humaine
US7862817B2 (en) 1999-06-25 2011-01-04 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
WO2011014469A1 (fr) 2009-07-29 2011-02-03 Regeneron Pharmaceuticals, Inc. Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine
US20110150895A1 (en) 2009-12-15 2011-06-23 Samsung Electronics Co., Ltd. Antibody specifically binding to angiopoietin-2 and use thereof
WO2011117329A1 (fr) 2010-03-26 2011-09-29 F. Hoffmann-La Roche Ag Anticorps bispécifiques, bivalents anti-vegf/anti-ang-2
WO2012131078A1 (fr) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Molécules de liaison bispécifiques se liant à vegf et à ang2
WO2012143523A1 (fr) * 2011-04-20 2012-10-26 Genmab A/S Anticorps bispécifiques contre her2
WO2015091738A1 (fr) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Anticorps bispécifiques anti-het2 et leurs méthodes d'utilisation

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434A1 (fr) 1987-03-18 1989-03-22 Medical Res Council Anticorps alteres.
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
US7862817B2 (en) 1999-06-25 2011-01-04 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
WO2003030833A2 (fr) 2001-10-11 2003-04-17 Amgen Inc. Agents de liaison spécifiques de l'angiopoïétine-2
WO2006068953A2 (fr) 2004-12-21 2006-06-29 Astrazeneca Ab Anticorps dirigés contre l'angiopoïétine 2 et leurs utilisations
WO2009097325A1 (fr) 2008-01-28 2009-08-06 Medimmune Limited Anticorps stabilisés contre l'angiopoïétine-2 et leurs utilisations
WO2009105269A1 (fr) 2008-02-20 2009-08-27 Amgen Inc. Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
WO2010040508A1 (fr) 2008-10-08 2010-04-15 F. Hoffmann-La Roche Ag Anticorps anti-vegf/anti-ang-2 bispécifiques
WO2010069532A1 (fr) 2008-12-16 2010-06-24 F. Hoffmann-La Roche Ag Anticorps dirigés contre l'angiopoïétine 2 humaine
WO2011014469A1 (fr) 2009-07-29 2011-02-03 Regeneron Pharmaceuticals, Inc. Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine
US20110150895A1 (en) 2009-12-15 2011-06-23 Samsung Electronics Co., Ltd. Antibody specifically binding to angiopoietin-2 and use thereof
WO2011117329A1 (fr) 2010-03-26 2011-09-29 F. Hoffmann-La Roche Ag Anticorps bispécifiques, bivalents anti-vegf/anti-ang-2
WO2012131078A1 (fr) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Molécules de liaison bispécifiques se liant à vegf et à ang2
WO2012143523A1 (fr) * 2011-04-20 2012-10-26 Genmab A/S Anticorps bispécifiques contre her2
WO2015091738A1 (fr) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Anticorps bispécifiques anti-het2 et leurs méthodes d'utilisation

Non-Patent Citations (46)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE
BANGE ET AL., NATURE MEDICINE, vol. 7, 2001, pages 548
BARNES, L.M. ET AL., BIOTECH. BIOENG., vol. 73, 2001, pages 261 - 270
BARNES, L.M. ET AL., CYTOTECHNOLOGY, vol. 32, 2000, pages 109 - 123
BOACKLE, R.J. ET AL., NATURE, vol. 282, 1979, pages 742 - 743
BRUNHOUSE, R.; CEBRA, J.J., MOL. IMMUNOL., vol. 16, 1979, pages 907 - 917
BURTON, D.R. ET AL., NATURE, vol. 288, 1980, pages 338 - 344
CARTER, P. ET AL., PROC. NATL. ACAD. SCI., vol. 89, 1992, pages 4285 - 4289
CASCONE, T. ET AL., J CLIN ONCOL, vol. 30, 2012, pages 441 - 444
CHAE, S. S.; W. S. KAMOUN ET AL., CLIN CANCER RES, vol. 16, 2010, pages 3618 - 3627
CHEUNG, A.H. ET AL., GENOMICS, vol. 48, 1998, pages 389 - 91
DAVIES, S. ET AL., CELL, vol. 87, 1996, pages 1161 - 1169
DAVIS, S. ET AL., CELL, vol. 87, 1996, pages 1161 - 1169
DUROCHER, Y. ET AL., NUCL. ACIDS. RES., vol. 30, 2002, pages E9
FALCON, B. L.; H. HASHIZUME ET AL., AM J PATHOL, vol. 175, 2009, pages 2159 - 2170
GEISSE, S. ET AL., PROTEIN EXPR. PURIF., vol. 8, 1996, pages 271 - 282
HEZAREH, M. ET AL., J. VIROLOGY, vol. 75, 2001, pages 12161 - 12168
HOLASH, J. ET AL., ONCOGENE, vol. 18, 1999, pages 5356 - 62
HOLASH, J. ET AL., SCIENCE, vol. 284, 1999, pages 1994 - 98
IDUSOGIE, E.E. ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184
JOHNSON, G.; WU, T.T., NUCLEIC ACIDS RES., vol. 28, 2000, pages 214 - 218
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KAUFMAN, R.J., MOL. BIOTECHNOL., vol. 16, 2000, pages 151 - 161
KIM, I. ET AL., FEBS LET, vol. 443, 1999, pages 353 - 56
KIM, I. ET AL., J BIOL CHEM, vol. 274, 1999, pages 26523 - 28
KWAK, H.J. ET AL., FEBS LETT, vol. 448, 1999, pages 249 - 53
LI ET AL., CANCER RESEARCH, 2013
LUKAS, T.J. ET AL., J. IMMUNOL., vol. 127, 1981, pages 2555 - 2560
MAISONPIERRE, P.C. ET AL., SCIENCE, vol. 277, 1997, pages 55 - 60
MAKRIDES, S.C., PROTEIN EXPR. PURIF., vol. 17, 1999, pages 183 - 202
MORGAN, A. ET AL., IMMUNOLOGY, vol. 86, 1995, pages 319 - 324
NORDERHAUG, L. ET AL., J. IMMUNOL. METHODS, vol. 204, 1997, pages 77 - 87
ORLANDI, R. ET AL., PROC. NATL. ACAD. SCI., vol. 86, 1989, pages 3833 - 3837
SAHARINEN, P. ET AL., TRENDS MOL MED, vol. 17, 2011, pages 347 - 362
SCHLAEGER, E.-J., J. IMMUNOL. METHODS, vol. 194, 1996, pages 191 - 199
SCHLAEGER, E.-J.; CHRISTENSEN, K., CYTOTECHNOLOGY, vol. 30, 1999, pages 71 - 83
SURI, C. ET AL., SCIENCE, vol. 282, 1998, pages 468 - 71
THOMAS, M. ET AL., PLOS ONE, vol. 8, 2013, pages e54923
THOMMESEN, J.E. ET AL., MOL. IMMUNOL., vol. 37, 2000, pages 995 - 1004
THURSTON, G. ET AL., NAT. MED., vol. 6, 2000, pages 460 - 63
THURSTON, G. ET AL., SCIENCE, vol. 286, 1999, pages 2511 - 14
WERNER SCHEUER ET AL: "Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2", MABS, vol. 8, no. 3, 10 February 2016 (2016-02-10), US, pages 562 - 573, XP055372700, ISSN: 1942-0862, DOI: 10.1080/19420862.2016.1147640 *
WERNER, R.G., DRUG RES., vol. 48, 1998, pages 870 - 880
Y. KIENAST ET AL: "Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy", CLINICAL CANCER RESEARCH, vol. 19, no. 24, 4 October 2013 (2013-10-04), pages 6730 - 6740, XP055106066, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-13-0081 *
YANCOPOULOS, G. D. ET AL., NATURE, vol. 407, 2000, pages 242 - 248
YANCOPOULOS, G.D. ET AL., NATURE, vol. 407, 2000, pages 242 - 48

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11155610B2 (en) 2014-06-28 2021-10-26 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2022057888A1 (fr) * 2020-09-17 2022-03-24 江苏恒瑞医药股份有限公司 Molécule de liaison à l'antigène bispécifique se liant spécifiquement au vegf et à l'ang-2
CN116234574A (zh) * 2020-09-17 2023-06-06 江苏恒瑞医药股份有限公司 特异性结合vegf和ang-2的双特异性抗原结合分子

Similar Documents

Publication Publication Date Title
US20200199215A1 (en) Combination therapy with an anti-ang2 antibody and a cd40 agonist
US20200095313A1 (en) Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1
WO2016170039A1 (fr) Polythérapie d'anticorps se liant à l'angiopoïétine 2 avec un anticorps se liant au polypeptide de mort programmée 1
JP6457386B2 (ja) 抗−ｄｒ５ファミリー抗体、二重特異性又は多価の抗−ｄｒ５ファミリー抗体及びそれらの使用方法
CA2575901C (fr) Procede de traitement du cancer comprenant un antagoniste de vegf-b
US20180155431A1 (en) Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death ligand 1
AU2016248802B2 (en) Anti-human Notch 4 antibody
RU2644245C2 (ru) Анти-vegf-антитело и содержащая его фармацевтическая композиция для предупреждения, диагностики или лечения рака или связанного с ангиогенезом заболевания
CA2780692A1 (fr) Anticorps se liant de facon preferentielle au domaine extracellulaire 4 de csf1r humain et leur utilisation
WO2018114728A1 (fr) Polythérapie par anticorps bispécifique anti-ang2/vegf et anticorps bispécifique anti-her2
KR20220042258A (ko) 항 tigit 항체 및 그의 응용
EP3070102A1 (fr) Thérapie de combinaison a l'aide d'anticorps d'activation du cd40 humain et d'anticorps contre le récepteur humain pd-l1
CN114805581B (zh) 靶向il13ra2的抗体、嵌合抗原受体及其用途
WO2023109888A1 (fr) Anticorps bispécifique anti-ang2-vegf et son utilisation
WO2023041041A1 (fr) Molécules de liaison à d3 et leurs utilisations
CN114075288A (zh) 抗pd-l2抗体
AU2011265322A1 (en) A method of treating cancer comprising a VEGF-B antagonist

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17821554

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17821554

Country of ref document: EP

Kind code of ref document: A1